Detection of CD8+ T-cell responses to CGAg in PBMCs of patients with multiple myeloma
Salmon-Durie staging and patient no. . | Sex . | Age, y . | Monoclonal immunoglobulin . | Maximal CD8+ response to CGAg, as % of CD8+ pool . |
|---|---|---|---|---|
| I | ||||
| 1 | F | 68 | IgG | ND |
| 2 | M | 58 | IgG | 0.004 |
| 3 | M | 64 | κ | ND |
| 4 | M | 70 | IgA | 0.07 |
| 5 | M | 51 | IgG | ND |
| 6 | M | 37 | IgG | ND |
| 7 | F | 80 | IgG | 0.008 |
| 8 | F | 72 | IgG | ND |
| II | ||||
| 9 | M | 57 | IgG | 0.008 |
| 10 | M | 81 | IgA | ND |
| 11 | F | 69 | IgG | 0.006 |
| 12 | F | 37 | IgG | ND |
| 14 | M | 59 | low IgA | ND |
| 15 | F | 74 | IgA | ND |
| 16 | M | 55 | IgG | ND |
| 17 | F | 75 | IgG | 0.015 |
| II/III | ||||
| 13 | M | 81 | IgG | 0.1 |
| 18 | F | 63 | κ | ND |
| IIIc | ||||
| 19 | F | 85 | IgG | ND |
| 20 | M | 60 | λ | 0.001 |
| 21 | M | 62 | IgG | 0.007 |
| 22 | F | 41 | λ | 0.01 |
| 23 | F | 59 | λ | 0.01 |
| 24 | F | 84 | IgG | ND |
| 25 | M | 66 | IgG | ND |
| 26 | M | 62 | IgG | ND |
| 27 | M | 56 | IgG | 0.016 |
| 28 | F | 78 | IgG | ND |
| 29 | M | 78 | IgA | ND |
| 30 | F | 81 | IgG | 0.005 |
| 31 | F | 53 | λ | ND |
| 32 | F | 60 | λ | ND |
| 33 | M | 55 | IgA | ND |
| 34 | M | 75 | IgD | ND |
| 35 | M | 69 | IgG | ND |
| 36 | F | 69 | IgG | 0.003 |
| 37 | F | 65 | IgG | 0.035 |
Salmon-Durie staging and patient no. . | Sex . | Age, y . | Monoclonal immunoglobulin . | Maximal CD8+ response to CGAg, as % of CD8+ pool . |
|---|---|---|---|---|
| I | ||||
| 1 | F | 68 | IgG | ND |
| 2 | M | 58 | IgG | 0.004 |
| 3 | M | 64 | κ | ND |
| 4 | M | 70 | IgA | 0.07 |
| 5 | M | 51 | IgG | ND |
| 6 | M | 37 | IgG | ND |
| 7 | F | 80 | IgG | 0.008 |
| 8 | F | 72 | IgG | ND |
| II | ||||
| 9 | M | 57 | IgG | 0.008 |
| 10 | M | 81 | IgA | ND |
| 11 | F | 69 | IgG | 0.006 |
| 12 | F | 37 | IgG | ND |
| 14 | M | 59 | low IgA | ND |
| 15 | F | 74 | IgA | ND |
| 16 | M | 55 | IgG | ND |
| 17 | F | 75 | IgG | 0.015 |
| II/III | ||||
| 13 | M | 81 | IgG | 0.1 |
| 18 | F | 63 | κ | ND |
| IIIc | ||||
| 19 | F | 85 | IgG | ND |
| 20 | M | 60 | λ | 0.001 |
| 21 | M | 62 | IgG | 0.007 |
| 22 | F | 41 | λ | 0.01 |
| 23 | F | 59 | λ | 0.01 |
| 24 | F | 84 | IgG | ND |
| 25 | M | 66 | IgG | ND |
| 26 | M | 62 | IgG | ND |
| 27 | M | 56 | IgG | 0.016 |
| 28 | F | 78 | IgG | ND |
| 29 | M | 78 | IgA | ND |
| 30 | F | 81 | IgG | 0.005 |
| 31 | F | 53 | λ | ND |
| 32 | F | 60 | λ | ND |
| 33 | M | 55 | IgA | ND |
| 34 | M | 75 | IgD | ND |
| 35 | M | 69 | IgG | ND |
| 36 | F | 69 | IgG | 0.003 |
| 37 | F | 65 | IgG | 0.035 |
The CGAg-specific peptide response was calculated as a percentage of the total CD8+ T-cell pool (see “Materials and methods”).
ND indicates that responses were undetectable.